Skip to main content

Table 2 Data of the cross sectional study.

From: Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients

 

All patients

Patients with BP-ONJ

Patients without BP-ONJ

Difference

Number (percentage)

78 (100%)

16 (21%)

62 (80%)

 

Age at examination (SD)

63.5 (10.1)

61.9 (21.0)

64.1 (10.5)

p = 0.18

Age at MM diagnosis

59.8 (11.1)

54.1 (8.8)

61.3 (11.2)

p = 0.02

Men

47

9

38

p = 0.78

Women

31

7

24

 

MM stage I

17 (22%)

3 (4%)

14 (18%)

 

MM stage II

13 (17%)

2 (3%)

11 (14%)

p = 0.79

MM stage III

48 (62%)

11 (14%)

37 (47%)

 

Bisphosphonate infusions

28.1

48.4 (range 9 - 111)

23.3 (range 1 - 104)

p < 0.001

Zoledronate

    

Patients

49 (63%)

4 (5%)

45 (58%)

 

Infusions

15

21

15

 

Pamidronate + zoledronate

    

Patients (percentage)

20 (26%)

9 (12%)

11 (14%)

 

infusions

33, 22

26, 30

39, 15

 

Ibandronate + zoledronate

   

p = 0.001

Patients (percentage)

6 (8%)

1 (1%)

5 (6%)

 

infusions

6, 15

4, 28

7, 12

 

Pamidronate + zoledronate + ibandroante

    

Patients (percentage)

3 (4%)

2 (3%)

1 (%)

 

infusions

38, 20, 5

27, 28, 3

59, 5, 10

 

Corticosteroids

59 (76%)

13 (17%)

46 (61%)

p = 0.75

Chemotherapy

64 (82%)

13 (17%)

51 (67%)

p = 1.0

Diabetes mellitus

6 (8%)

2 (3%)

4 (5%)

p = 0.6

Further malignant diseases

3 (4%)

0

3 (4%)

p = 1.0

Smoker

8 (10%)

1 (1%)

7 (9%)

p = 1.0

Patients with all teeth in situ

8 (10%)

0

8 (10%)

p = 0.2

Caries

16 (21%)

2 (3%)

14 (18%)

p = 0.50

Denture

37 (47%)

9 (12%)

28 (36%)

p = 0.58

  1. P-values were calculated with the Mann-Whitney-Test and the Fisher's exact test and the Pearsons's Chi-Quadrate-Test. Abbreviations: BP-ONJ, bisphosphonate associated osteonecrosis of the jaws; SD, standard deviation; MM, multiple myeloma; +, sequent